This website is intended for US healthcare professionals.

Mechanism
of Action

EKTERLY delivers rapid PKa inhibition without a needle1

EKTERLY begins blocking upstream PKa activity within minutes1

Tap here to see full image. Hypothetical EKTERLY® (sebetralstat) patient, smiling
  • MOD for HAE and EKTERLY® (sebetralstat) MOA arrow

    In patients with HAE, PKa becomes dysregulated1,2

  • MOD for HAE and EKTERLY® (sebetralstat) MOA arrow

    Overactive PKa activity leads to increased vascular permeability1,2

  • MOD for HAE and EKTERLY® (sebetralstat) MOA

    Excessive fluid leaks into surrounding tissues, resulting in edema1,2

  • MOD for HAE and EKTERLY® (sebetralstat) MOA

    EKTERLY inhibits PKa, halting HAE attack progression1

  • EKTERLY is rapidly absorbed in the stomach and duodenum3,4
  • Absorption occurs higher in the gastrointestinal tract than where abdominal attacks most
    frequently occur3,4

Begins suppression of PKa in as little as

15
minutes after oral administration5*
Hypothetical EKTERLY® (sebetralstat) patient Hypothetical EKTERLY® (sebetralstat) patient Actor portrayal
UP NEXT:
Patient SupportRight arrow

*Based on 600-mg data from a phase 2 trial.5

HAE=hereditary angioedema; PKa=plasma kallikrein.

References:
1. EKTERLY. Package insert. KalVista Pharmaceuticals, Inc.; 2025. 2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 3. Davie RL, Edwards HJ, Evans DM, et al. Sebetralstat (KVD900): A potent and selective small molecule plasma kallikrein inhibitor featuring a novel P1 group as a potential oral on-demand treatment for hereditary angioedema. J Med Chem. 2022;65(20):13629-13644. doi:10.1021/acs.jmedchem.2c00921 4. De Backer AI, De Schepper AM, Vandevenne JE, Schoeters P, Michielsen P, Stevens WJ. CT of angioedema of the small bowel. AJR Am J Roentgenol. 2001;176(3):649-652. doi:10.2214/ajr.176.3.1760649
5. Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. N Engl J Med. 2024;391(1):32-43. doi:10.1056/NEJMoa2314192

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

There are no available data on EKTERLY in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at 1-855-258-4782 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.